Assessment of safety during hospitalization for patients undergoing Surgery after neoadjuvant therapy for moderately advanced Esophageal cancer.

PURPOSE: To study the safety of patients with moderately advanced esophageal cancer during their hospital stay after undergoing surgery. METHODS: The clinical and pathological data of 66 patients with locally advanced esophageal cancer discharged from the Department of Thoracic Surgery of Jiangsu University Hospital from January 2017 to October 2022 were selected, of whom 32 underwent direct surgery (control group) and 34 underwent neoadjuvant therapy followed by surgery (experimental group), to retrospectively analyze whether there were differences in surgical outcomes, complication rates, biochemical and infection indicators between the two groups. RESULTS: The number of lymph node dissections, lymph node dissection rate, and hemoglobin value on the first day after the operation in the experimental group were smaller than those in the control group, and the difference was statistically significant (P < 0.05). The thoracic drainage volume of the experimental group was more than that of the control group, and the difference was statistically significant (P < 0.05). The incidence of pulmonary complications in the experimental group was higher than that in the control group, especially pulmonary infection, and the difference was statistically significant (P < 0.05). Compared with the control group, the experimental group was more prone to anastomotic leakage, and the difference was statistically significant (P < 0.05). CONCLUSION: Neoadjuvant therapy combined with surgery for patients with advanced esophageal cancer is generally safe during hospitalization.

The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers.

Myeloid-derived suppressor cells (MDSCs) are an immature group of myeloid-derived cells generated from myeloid cell precursors in the bone marrow. MDSCs appear almost exclusively in pathological conditions, such as tumor progression and various inflammatory diseases. The leading function of MDSCs is their immunosuppressive ability, which plays a crucial role in tumor progression and metastasis through their immunosuppressive effects. Since MDSCs have specific molecular features, and only a tiny amount exists in physiological conditions, MDSC-targeted therapy has become a promising research direction for tumor treatment with minimal side effects. In this review, we briefly introduce the classification, generation and maturation process, and features of MDSCs, and detail their functions under various circumstances. The present review specifically demonstrates the environmental specificity of MDSCs, highlighting the differences between MDSCs from cancer and healthy individuals, as well as tumor-infiltrating MDSCs and circulating MDSCs. Then, we further describe recent advances in MDSC-targeted therapies. The existing and potential targeted drugs are divided into three categories, monoclonal antibodies, small-molecular inhibitors, and peptides. Their targeting mechanisms and characteristics have been summarized respectively. We believe that a comprehensive in-depth understanding of MDSC-targeted therapy could provide more possibilities for the treatment of cancer.

Combination of a surgical template and a collagen strip for guiding sinus floor elevation in the oblique sinus floor: A technical note.

Sinus floor elevation (SFE) by transcrestal approach has been proven to be a predictable and minimally invasive treatment that augments posterior maxilla with insufficient bone height, allowing the prosthetic rehabilitation of this area with dental implants. However, precise and sufficient elevation of the Schneiderian membrane without perforation is challenging through this blind technique especially in the presence of anatomical restrictions. This note describes a novel technique combining a surgical template and an absorbable collagen sponge (ACS) strip for transcrestal SFE in the oblique sinus floor. A surgical template was used to locate the oblique sinus floor and a collagen strip was placed to orient membrane elevation, meanwhile, protect the sinus membrane. Within the limits of present observation, this technique may increase the manipuility while reducing the risk of complications.

Using the intact periosteum for horizontal bone augmentation of peri-implant defects: a retrospective cohort study.

The objectives of this study were to observe hard tissue changes in guided bone regeneration (GBR) with intact periosteum and soft block deproteinised bovine bone mineral (DBBM), and evaluate whether the result of horizontal bone augmentation varied by initial peri-implant defect depth. Forty patients with a single missing tooth and contained peri-implant defect were categorised into three groups according to their presurgical defect depth (≤ 2, 2-4, and 4-6 mm). Cone-beam computed tomography (CBCT) images were collected and reconstructed preoperatively, postoperatively, and at six months' follow up. The buccal bone width (BBW -0, -3, -5), alveolar bone width (ABW -0, -3, -5) and volume of augmented area were measured. At the six-month follow up the increase in BBW, ABW at all levels, and in bone volume, was statistically significant (all p < 0.001). No statistical significance in bone dimensions or bone resorption was found among groups (all p > 0.05). Histological analysis detected new bone formation in intimate contact with bone grafts underlying the periosteum. Within the limitations of this study, the insights gained may be of assistance to suggest that comparable and acceptable results of horizontal bone augmentation can be achieved in cases of peri-implant defect depth of ≤6 mm by means of GBR with intact periosteum.